Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway
Cancer Letters · 2023
DOI: 10.1016/j.canlet.2023.216142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2023. Verfasst von Yuzhu Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China; Breast Department, Guangdong …. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) has a poor prognosis due to the lack of specific and highly effective therapeutic agents. Cancer stem cells (CSCs) are one of the main factors contributing to TNBC relapse and metastasis. Therefore, targeting CSCs selectively with small molecules is a novel strategy for drug development. In this study, the natural product harmine (HM) was identified as a hit compound from 2632 natural product monomers based on phenotypic screening of a 2D assay and patient-derived organoid (PDO) model that was established from a patient who had multiple drug resistance and various visceral and contralateral breast metastases. Next, harmine was further modified and optimized to obtain a lead compound (YH677) with a tetrahydro-β-carboline scaffold. YH677 showed potent antiproliferative and antimigratory activities against several TNBC cell lines in vitro. In addition, YH677 inhibited epithelial mesenchymal transition (EMT) and stem cell marker expression in a dose-dependent manner. More importantly, YH677 suppressed breast cancer growth and metastasis in orthotopic, metastatic xenograft and patient-derived xenograft (PDX) models in vivo. Mechanistic studies showed that YH677 inhibits the expansion of CSCs by regulating the TGFβ/Smad signaling pathway. These preclinical data provide a basis for the development of YH677 as a lead compound for TNBC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China; Breast Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
- School of Basic Medical Sciences, Ningxia Medical University, Ningxia, 750004, China; Key Laboratory of Fertility Maintenance Ministry of Education, Ningxia Medical University, Ningxia, 750004, China.
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai,…
- Breast Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China.
- Breast Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China. Electronic address: cqj55@163.com.
- National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. Electronic address: huangluqi01@126.com.
Zitieren
APA
Zhang, Y., Chen, J., Mi, D., Ling, J., Li, H., He, P., Liu, N., Chen, Q., Chen, Y., & Huang, L. (2023). Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216142
Vancouver
Zhang Y, Chen J, Mi D, Ling J, Li H, He P, et al. Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216142
BibTeX
@article{Zhang2023,
author = {Zhang, Yuzhu and Chen, Jing and Mi, Dazhao and Ling, Jun and Li, Huachao and He, Peng and Liu, Ning and Chen, Qianjun and Chen, Yihua and Huang, Luqi},
title = {Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway},
journal = {Cancer Letters},
year = {2023},
doi = {10.1016/j.canlet.2023.216142}
}
EUVIMED